229,95 €
229,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
115 °P sammeln
229,95 €
229,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
115 °P sammeln
Als Download kaufen
229,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
115 °P sammeln
Jetzt verschenken
229,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
115 °P sammeln
  • Format: PDF

The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene

Produktbeschreibung
The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Roger Bertolotti, CNRS, Molecular Genetics, Department of Hepato-Gastroenterology, Faculty of Medicine, University of Nice-Sophia Antipolis, France. Keiyo Ozawa, Division of Hematology, Department of Medicine, and Division of Cell Transplantation and Transfusion, and Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Japan. H. Kirk Hammond, Division of Cardiology, VA San Diego Healthcare System and University of California, San Diego School of Medicine, San Diego, California.